GlobeNewswire BiotechnologyCodex · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 20:00:00·⟳ 抓取 20:06:58·⚡ 决策 09-01 22:49:14 +2h42m·55.9 天前
Scribe Therapeutics宣布参加三场投资者会议，未披露新增临床、合作或财务进展
本次公告只是投资者会议日程，未带来临床、监管、商业化、合作或财务增量，行情和先例研究不可能改变不交易结论。
📄 原文GlobeNewswire Biotechnology↗ 原文
Scribe Therapeutics to Participate in Upcoming Investor Conferences
ALAMEDA, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. (“Scribe Therapeutics”) (Nasdaq: SCTX), a…
不做 Scribe Therapeutics Inc.（SCTX.US）
例行投资者会议公告无新增临床、合作、监管或财务事实，缺少可交易edge。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Scribe Therapeutics发布的是例行投资者会议参与公告，核心事实仅为CEO/CFO将在未来会议中发言；公告没有新增试验数据、监管里程碑、合作付款、商业化进展或财务指引，因此对SCTX.US及其合作方没有可交易的基本面增量。
🔎 新鲜度:最早出现 2026-09-01 · 扩散 low · price-in 风险 low ↗
主要风险
- 若会议期间另行披露临床数据、合作扩展或融资安排，需要作为新事件重新研判。
先例如何影响了这次决策
对本次决策的影响:事件本身已足以判定无正期望交易，未进行先例研究。
方向:例行会议参与公告缺少可测的基本面冲击，未使用历史先例校准方向。
涨幅量级:无新增金额、数据或里程碑，无法用先例校准幅度。
形态:不适用。
原文全文
展开原文 · 2,271 字
ALAMEDA, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. (“Scribe Therapeutics”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention, today announced that management will participate in the following upcoming investor conferences:
Wells Fargo Healthcare Conference
Boston, MA
Sept. 9, 2026 at 8:00 AM ET
Benjamin Oakes, Ph.D., Co-founder and CEO, will participate in a fireside chat.
H.C. Wainwright 28th Annual Global Investment Conference
New York, NY
Sept. 15, 2026
Benjamin Oakes, Ph.D., Co-founder and CEO, will present.
Cell & Gene Meeting on the Mesa
Phoenix, AZ
Oct. 5, 2026 at 5:15 PM MT
David Parrot, M.B.A., CFO, will deliver an Innovation Spotlight presentation.
About Scribe Therapeutics Inc.
Scribe Therapeutics is a clinical-stage biotechnology company engineering CRISPR-based technologies into purpose-built in vivo genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases, starting with cardiometabolic disease. Leveraging its CRISPR by Design™ approach and nature’s blueprint for improved cardiovascular health, Scribe’s initial programs focus on addressing the key drivers of ASCVD such as elevated LDL-C, lipoprotein(a), and triglycerides. The company’s lead candidate, STX-1150, is a novel liver-targeted therapy designed to epigenetically silence the PCSK9 gene and reduce LDL-C levels without inducing permanent DNA changes. To broaden and accelerate the impact of its engineered CRISPR technologies for patients, Scribe has formed strategic collaborations with world-leading pharmaceutical companies including Sanofi and Eli Lilly. Co-founded by Nobel Prize winner Jennifer Doudna and backed by leading life sciences investors, Scribe is advancing scalable, transformative, and preventative genetic medicines with the goal of improving outcomes and democratizing access to the protective effects of beneficial human genetics. To learn more, visit
www.scribetx.com
.
Investor Contact:
Investor Relations, Scribe Therapeutics
ir@scribetx.com
Media Contact:
Thermal for Scribe Therapeutics
media@scribetx.com
Wells Fargo Healthcare Conference
Boston, MA
Sept. 9, 2026 at 8:00 AM ET
Benjamin Oakes, Ph.D., Co-founder and CEO, will participate in a fireside chat.
H.C. Wainwright 28th Annual Global Investment Conference
New York, NY
Sept. 15, 2026
Benjamin Oakes, Ph.D., Co-founder and CEO, will present.
Cell & Gene Meeting on the Mesa
Phoenix, AZ
Oct. 5, 2026 at 5:15 PM MT
David Parrot, M.B.A., CFO, will deliver an Innovation Spotlight presentation.
About Scribe Therapeutics Inc.
Scribe Therapeutics is a clinical-stage biotechnology company engineering CRISPR-based technologies into purpose-built in vivo genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases, starting with cardiometabolic disease. Leveraging its CRISPR by Design™ approach and nature’s blueprint for improved cardiovascular health, Scribe’s initial programs focus on addressing the key drivers of ASCVD such as elevated LDL-C, lipoprotein(a), and triglycerides. The company’s lead candidate, STX-1150, is a novel liver-targeted therapy designed to epigenetically silence the PCSK9 gene and reduce LDL-C levels without inducing permanent DNA changes. To broaden and accelerate the impact of its engineered CRISPR technologies for patients, Scribe has formed strategic collaborations with world-leading pharmaceutical companies including Sanofi and Eli Lilly. Co-founded by Nobel Prize winner Jennifer Doudna and backed by leading life sciences investors, Scribe is advancing scalable, transformative, and preventative genetic medicines with the goal of improving outcomes and democratizing access to the protective effects of beneficial human genetics. To learn more, visit
www.scribetx.com
.
Investor Contact:
Investor Relations, Scribe Therapeutics
ir@scribetx.com
Media Contact:
Thermal for Scribe Therapeutics
media@scribetx.com
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。